N
Nathalie Jacque
Researcher at French Institute of Health and Medical Research
Publications - 15
Citations - 902
Nathalie Jacque is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 6, co-authored 13 publications receiving 739 citations. Previous affiliations of Nathalie Jacque include Centre national de la recherche scientifique & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Nathalie Jacque,Anne Marie Ronchetti,Clément Larrue,Clément Larrue,Godelieve Meunier,Rudy Birsen,Lise Willems,Estelle Saland,Estelle Saland,Justine Decroocq,Thiago Trovati Maciel,Mireille Lambert,Laury Poulain,Pierre Sujobert,Laure Joseph,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Ivan C. Moura,Susan Demo,Jean-Emmanuel Sarry,Jean-Emmanuel Sarry,Christian Recher,Christian Recher,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Didier Bouscary +28 more
TL;DR: It is shown that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells and targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.
Journal ArticleDOI
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Lise Willems,Lise Willems,Nathalie Jacque,Arnaud Jacquel,Nathalie Neveux,Thiago Trovati Maciel,Mireille Lambert,Alain Schmitt,Laury Poulain,Alexa S. Green,Madalina Uzunov,Olivier Kosmider,Olivier Kosmider,Isabelle Radford-Weiss,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Valérie Bardet,Valérie Bardet,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Jerome Tamburini,Didier Bouscary,Didier Bouscary +28 more
TL;DR: It is shown that glutamine removal inhibits mTORC1 and induces apoptosis in AML cells, and that l-ases upregulate glutamine synthase expression in leukemic cells and that a GS knockdown enhances l-ase-induced apoptotic response in someAML cells.
Journal ArticleDOI
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Lise Willems,Nicolas Chapuis,Nicolas Chapuis,Alexandre Puissant,Thiago Trovati Maciel,Alexa S. Green,Alexa S. Green,Nathalie Jacque,Nathalie Jacque,Christine Vignon,Sophie Park,Sophie Park,Sylvie Guichard,Olivier Herault,Aurélie Fricot,Olivier Hermine,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Francois Dreyfus,Dominique Bonnet,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Jerome Tamburini,Jerome Tamburini +27 more
TL;DR: AZD8055 decreased AML blast cell proliferation and cell cycle progression, reduced the clonogenic growth of leukemic progenitors and induced caspase-dependent apoptosis inLeukemic cells but not in normal immature CD34+ cells, and induced autophagy, which may be either protective or cell death inducing, depending on concentration.
Journal ArticleDOI
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
Pierre Sujobert,Laury Poulain,Etienne Paubelle,Florence Zylbersztejn,Adrien Grenier,Mireille Lambert,Elizabeth C. Townsend,Jean-Marie Brusq,Edwige Nicodeme,Justine Decrooqc,Ina Nepstad,Alexa S. Green,Johanna Mondesir,Nathalie Jacque,Alexandra N. Christodoulou,Tiffany DeSouza,Olivier Hermine,Marc Foretz,Benoit Viollet,Catherine Lacombe,Patrick Mayeux,David M. Weinstock,Ivan C. Moura,Didier Bouscary,Jerome Tamburini +24 more
TL;DR: It is reported that the specific AMPK agonist GSK621 selectively kills acute myeloid leukemia (AML) cells but spares normal hematopoietic progenitors, which results from a unique synthetic lethal interaction involving concurrent activation of AMPK and mTORC1.
Journal ArticleDOI
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
Alexa S. Green,Thiago Trovati Maciel,Chae Yin,Fetta Mazed,Fetta Mazed,Elizabeth C. Townsend,Sylvain Pilorge,Mireille Lambert,Mireille Lambert,Etienne Paubelle,Arnaud Jacquel,Florence Zylbersztejn,Justine Decroocq,Laury Poulain,Laury Poulain,Pierre Sujobert,Pierre Sujobert,Nathalie Jacque,Nathalie Jacque,Kevin Adam,Kevin Adam,Jason C. C. So,Olivier Kosmider,Olivier Kosmider,Patrick Auberger,Olivier Hermine,David M. Weinstock,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Gary J. Vanasse,Anskar Y.H. Leung,Ivan C. Moura,Didier Bouscary,Didier Bouscary,Jerome Tamburini,Jerome Tamburini +37 more
TL;DR: It is found that Pim kinases governFLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors, which represents a promising new avenue for AML therapy.